Gilead announces $8M in funding through Gilead Relink program

Gilead Sciences is providing a total of $8M in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus or hepatitis B virus back into care. The CDA Foundation based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overseeing Gilead Relink, including distributing funds to grantees identified by CDAF that meet certain criteria, integral strategic planning and technical assistance. The Gilead Relink grant program aims to identify and bridge the gaps that remain in linking people living with HCV and HBV back to necessary care and treatment by prioritizing three programmatic areas – utilizing evidence-based solutions, leveraging successful intervention and data collection models, and emphasizing knowledge sharing and convening.